The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
Open accessAbstract
Purpose: Based on 5-year or shorter-term follow-up data in recent randomized trials, adjuvant cisplatin-based chemotherapy is now generally recommended after complete surgical resection for patients with non–small-cell lung cancer (NSCLC). We evaluated the results of the International Adjuvant Lung Cancer Trial study with three additional years of follow-up. Patients and Methods: Patients with completely resected NSCLC were randomly assigned to three or four cycles of cisplatin-based chemotherapy or to observation. Cox models were used to evaluate treatment effect according to follow-up duration. Results: The trial included 1,867 patients with a median follow-up of 7.5 years. Results showed a beneficial effect of adjuvant chemotherapy on overall survival (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.02; P = .10) and on disease-free survival (HR, 0.88; 95% CI, 0.78 to 0.98; P = .02). However, there was a significant difference between the results of overall survival before and after 5 years of follow-up (HR, 0.86; 95% CI, 0.76 to 0.97; P = .01 v HR, 1.45; 95% CI, 1.02 to 2.07; P = .04) with P = .006 for interaction. Similar results were observed for disease-free survival. The analysis of non-lung cancer deaths for the whole period showed an HR of 1.34 (95% CI, 0.99 to 1.81; P = .06). Conclusion: These results confirm the significant efficacy of adjuvant chemotherapy at 5 years. The difference in results beyond 5 years of follow-up underscores the need for the long-term follow-up of other adjuvant lung cancer trials and for a better identification of patients deriving long-term benefit from adjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Self-citationNon-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationA note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Self-citation
Cited by
Treatment of Stage I and II Non-small Cell Lung Cancer
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013) · Chest · doi:10.1378/chest.12-2359 · Cited by 1,440
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Goldstraw, P., Ball, D., Jett, J. R., Le Chevalier, T., Lim, E., Nicholson, A. G., & Shepherd, F. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62101-0 · Cited by 711
Self-citationNon‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study
Hosny, A., Parmar, C., Coroller, T. P., Grossmann, P., Zeleznik, R., Kumar, A., Bussink, J., Gillies, R. J., Mak, R. H., & Aerts, H. J. W. L. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002711 · Cited by 579
“more detailed stratification could potentially inform surgical approaches and techniques, empower high-risk patients with the choice of adjuvant therapy modalities that best fit their desired lifestyles, and identify long-term beneficiaries from such therapy [86].”
BackgroundLung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Felip, E., Rosell, R., Maestre, J. A., Rodríguez-Paniagua, J. M., Morán, T., Astudillo, J., Alonso, G., Borro, J. M., González-Larriba, J. L., Torres, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6204 · Cited by 430
Butts, C. A., Ding, K., Seymour, L., Twumasi-Ankrah, P., Graham, B., Gandara, D., Johnson, D. H., Kesler, K. A., Green, M., Vincent, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0333 · Cited by 425
Kris, M. G., Gaspar, L. E., Chaft, J. E., Kennedy, E. B., Azzoli, C. G., Ellis, P. M., Lin, S. H., Pass, H. I., Seth, R., Shepherd, F. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4401 · Cited by 368
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
Burdett, S., Pignon, J. P., Tierney, J., Tribodet, H., Stewart, L., Le Pechoux, C., Aupérin, A., Le Chevalier, T., Stephens, R. J., Arriagada, R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011430 · Cited by 360
Self-citationPrognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
Brambilla, E., Le Teuff, G., Marguet, S., Lantuejoul, S., Dunant, A., Graziano, S., Pirker, R., Douillard, J.-Y., Le Chevalier, T., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 349
Self-citationKratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z.-H., Gao, W., Pham, P. T., Mulvihill, M. S., Ziaei, F., Zhang, H., Su, B., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61941-7 · Cited by 333
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., Jiao, X., Xie, W., Kong, X., Vaz, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2054-x · Cited by 330
Shepherd, F. A., Domerg, C., Hainaut, P., Jänne, P. A., Pignon, J.-P., Graziano, S., Douillard, J.-Y., Brambilla, E., Le Chevalier, T., Seymour, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1390 · Cited by 293
Self-citationManagement of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 283
A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer
Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Sayols, S., Moran, S., Heyn, H., Vizoso, M., Gomez, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5516 · Cited by 278
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
Nagasaka, M., & Gadgeel, S. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1409624 · Cited by 270
Vaidya, P., Bera, K., Gupta, A., Wang, X., Corredor, G., Fu, P., Beig, N., Prasanna, P., Patil, P. D., Velu, P. D., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30002-9 · Cited by 134
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
Self-citationChaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829923ec · Cited by 122
Tang, F., Tie, Y., Lan, T., Yang, J., Hong, W., Chen, S., Shi, H., Li, L., Zeng, H., Min, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202207518 · Cited by 34
Metadata
- Authors
- Arriagada, R., Dunant, A., Pignon, J.-P., Bergman, B., Chabowski, M., Grunenwald, D., Kozlowski, M., Le Péchoux, C., Pirker, R., Pinel, M.-I. S., Tarayre, M., & Le Chevalier, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-01
- Volume
- 28
- Issue
- 1
- Pages
- 35-42
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104543228
- Cited by
- 394
- References
- 31
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.